Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging

The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regress...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafiq, Arsalan, Chughtai, Tausif, Ashraf, Umair, Patel, Yash, Raiszadeh, Farbod, Sklyar, Eduard, Afshar, Maryam, Bella, Jonathan N., Kamalakkannan, Gayathri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474107/
https://www.ncbi.nlm.nih.gov/pubmed/32861387
http://dx.doi.org/10.1016/j.ihj.2020.06.015
_version_ 1783579284028260352
author Rafiq, Arsalan
Chughtai, Tausif
Ashraf, Umair
Patel, Yash
Raiszadeh, Farbod
Sklyar, Eduard
Afshar, Maryam
Bella, Jonathan N.
Kamalakkannan, Gayathri
author_facet Rafiq, Arsalan
Chughtai, Tausif
Ashraf, Umair
Patel, Yash
Raiszadeh, Farbod
Sklyar, Eduard
Afshar, Maryam
Bella, Jonathan N.
Kamalakkannan, Gayathri
author_sort Rafiq, Arsalan
collection PubMed
description The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance.
format Online
Article
Text
id pubmed-7474107
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74741072020-09-15 Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging Rafiq, Arsalan Chughtai, Tausif Ashraf, Umair Patel, Yash Raiszadeh, Farbod Sklyar, Eduard Afshar, Maryam Bella, Jonathan N. Kamalakkannan, Gayathri Indian Heart J Research Brief The objective of our study is to assess change in QTc interval with Regadenoson administration during myocardial perfusion imaging (MPI). We conducted a retrospective, observational analysis of 1497 consecutive patients who underwent pharmacological radionuclide MPI. On multivariate logistic regression analyses, there was no statistical significance of QTc prolongation when adjusted for ischemia/fixed perfusion defect on MPI and QT prolonging medications being taken prior to stress testing. However, a positive stress ECG after Regadenoson injection had a statistical significance (p value 0.0004). Regadenoson is a safe drug for use in MPI with little, if any, side effects of major clinical significance. Elsevier 2020 2020-07-03 /pmc/articles/PMC7474107/ /pubmed/32861387 http://dx.doi.org/10.1016/j.ihj.2020.06.015 Text en © 2020 Cardiological Society of India. Published by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Brief
Rafiq, Arsalan
Chughtai, Tausif
Ashraf, Umair
Patel, Yash
Raiszadeh, Farbod
Sklyar, Eduard
Afshar, Maryam
Bella, Jonathan N.
Kamalakkannan, Gayathri
Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging
title Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging
title_full Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging
title_fullStr Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging
title_full_unstemmed Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging
title_short Regadenoson administration and QT interval prolongation during pharmacological radionuclide myocardial perfusion imaging
title_sort regadenoson administration and qt interval prolongation during pharmacological radionuclide myocardial perfusion imaging
topic Research Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474107/
https://www.ncbi.nlm.nih.gov/pubmed/32861387
http://dx.doi.org/10.1016/j.ihj.2020.06.015
work_keys_str_mv AT rafiqarsalan regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT chughtaitausif regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT ashrafumair regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT patelyash regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT raiszadehfarbod regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT sklyareduard regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT afsharmaryam regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT bellajonathann regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging
AT kamalakkannangayathri regadenosonadministrationandqtintervalprolongationduringpharmacologicalradionuclidemyocardialperfusionimaging

Ejemplares similares